Can animal models predict protection provided by meningococcal vaccines?

Finney, Michelle; Halliwell, Denise; Gorringe, Andrew

doi:10.1016/j.ddmod.2006.03.002

Cited by 2 publications

(2 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The murine model has been used to demonstrate meningococcal vaccines efficacy [44]. The comparison of the immune responses to polysaccharides in humans and mice shows considerable similarities between the two species [45].…”

Section: Discussionmentioning

confidence: 99%

Carrier priming effect of CRM 197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM 197 and diphtheria toxoid

Pecetta

Tontini

Faenzi

et al. 2016

Vaccine

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Carrier priming effect of CRM 197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM 197 and diphtheria toxoid

Pecetta

Tontini

Faenzi

et al. 2016

Vaccine

View full text Add to dashboard Cite

“…As the presence of serum bactericidal activity predicts vaccine efficacy, serum bactericidal assay (SBA) is performed to analyze complementmediated vaccine-induced immune response [35]. Other serological tests that may be employed as indicative of vaccine imparted immunity include opsonophagocytosis assay (OPA) to determine opsonin function along with whole blood assay for cytokine level assessment [36,37]. However, determination of strain coverage by SBA is complex and hampered by the small volumes of sera that can be obtained in clinical trials, particularly with infants.…”

Section: Serological Tests For Assessing Vaccine Imparted Immunitymentioning

confidence: 99%

Preclinical Studies and Clinical Trials in Determination of Safety and Efficacy of Meningococcal Vaccines: Present Scenario

Majee¹,

Pal

2021

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Meningitis, a serious communicable inflammatory disease continues to be a worldwide threat especially in sub-Saharan Africa affecting millions of people with high death rates every year. Strains from six serogroups of the principal causative organism Neisseria meningitidis are found to be responsible for the majority of infections. Incidences of antibiotic resistance and efforts to provide mass protection have necessitated the development of meningococcal vaccines since the latter half of the 20th century. Aiming to ostracize meningitis by 2030, the World Health Organization focuses on vaccination as an important strategy to reach the goal. Due to limited efficacy and stability issues of earlier polysaccharide and protein conjugate vaccines respectively, outer membrane vesicle (OMV) vaccines were developed. Gene manipulations have also led to the development of more efficacious tailor-made OMV vaccines due to over-expression of antigenic outer membrane proteins along with lesser pyrogenicity. Available data from preclinical studies in animal models and clinical trials, on meningococcal vaccine candidates report the strength of immune response measured by serological tests such as enzyme-linked immunosorbent assay and serum bactericidal assay. Post-immunization adverse reactions have been also monitored as a part of safety assessment. The novelty of the present review lies in summarizing the outcomes of the preclinical animal studies and clinical trials conducted on various types of meningococcal vaccines till date and thereby highlighting the paucities in the existing information which can facilitate understanding the present scenario, challenges, and future scope in the field of meningococcal vaccine development.

show abstract

Can animal models predict protection provided by meningococcal vaccines?

Cited by 2 publications

References 20 publications

Carrier priming effect of CRM 197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM 197 and diphtheria toxoid

Carrier priming effect of CRM 197 is related to an enhanced B and T cell activation in meningococcal serogroup A conjugate vaccination. Immunological comparison between CRM 197 and diphtheria toxoid

Preclinical Studies and Clinical Trials in Determination of Safety and Efficacy of Meningococcal Vaccines: Present Scenario

Contact Info

Product

Resources

About